<DOC>
	<DOCNO>NCT01426126</DOCNO>
	<brief_summary>Taxane-based chemotherapy currently one commonly use regimen salvage chemotherapy advanced urothelial carcinoma . In previously untreated patient , single-agent paclitaxel , administer 24-hour infusion , produce overall response rate 42 % , single-agent docetaxel first-line therapy produce response rate 31 % 45 % 11 patient impaired renal function . Of two taxanes , paclitaxel study extensively . Intravenous administration paclitaxel require use solubilizing agent Cremophor EL ( CrEL ) due hydrophobicity . CrEL often contribute hypersensitivity reaction include hypotension dyspnea bronchospasm , major potentially life-threatening . Minor allergic reaction transient rash flush also may occur . Despite pretreatment corticosteroid histamine antagonist , minor reaction still occur 10-44 % patient , 1-3 % patient experience potentially fatal reaction . CrEL may also act potential cofactor development peripheral neuropathy . In addition , special infusion set must use clinically administer CrEL-based paclitaxel . Genexol-PM ( Samyang Co. , Seoul , Korea ) , form paclitaxel formulate sterile , lyophilized polymeric micells allow intravenous delivery paclitaxel without CrEL . The polymeric micelle formulation compose hundred low molecular weight , nontoxic , biodegradable amphiphilic diblock copolymer include monomethoxy poly ( ethylene glycol ) -block-poly ( D , L-lactide ) , great potential term water solubility , vivo stability , nanoscopic size ( diameter 20-50 nm ) micellar structure . A phase I study establish Genexol-PM administer 390 mg/m2 intravenously 3 h every 3 week maximum tolerable dose ( MTD ) human . Dose-limiting toxicity neuropathy , myalgia , neutropenia . No hypersensitivity reaction observe patient despite absence antiallergic premedication . The recommended dosage phase II study 300 mg/m2 . Based promising result taxane-based chemotherapy absence standard second-line chemotherapy regimen advance urothelial cancer , investigator design phase II study explore efficacy safety Genexol-PM advance urothelial patient , previously treat gemcitabine plus platinum adjuvant chemotherapy 1st line therapy metastatic disease .</brief_summary>
	<brief_title>Study Genexol-PM Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine Platinum</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologically confirm TCC urothelial tract ( bladder , renal pelvis , ureter ) 2 . Prior exposure gemcitabineplatinum regimen either adjuvant palliative chemotherapy . 3 . Unidimensionally measurable disease outside prior radiotherapy port 4 . Age 18 year old 5 . ECOG performance status 0~2 6 . Life expectancy least 3 month 7 . Adequate BM function ( ANC &gt; 1,500/mm3 &amp; Platelet &gt; 100,000/mm3 ) 8 . Adequate hepatic function ( Bilirubin great 2 time upper limit normal ( ULN ) &amp; AST ALT great 2.5 time ULN ) , renal function ( creatinine &lt; 1.5 X time ULN ) 9 . No preexist clinically significant grade 2 great neuropathy 1 . Pregnant lactate patient 2 . Presence history CNS metastasis 3 . Patients prior RT axial skeleton within 4 week chemotherapy start great 25 % bone marrow 4 . Any preexist medical condition sufficient severity prevent full compliance study , include active infection , active cardiac symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>urothelial carcinoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>platinum</keyword>
	<keyword>refractory</keyword>
	<keyword>salvage chemotherapy</keyword>
</DOC>